FDA panel votes 8-5 that breo ellipta helps reduce lung disease severity (THRX) (GSK)
Tweet
Share
E-mailGet Alerts THRX Hot Sheet
Join SI Premium – FREE
Theravance, Inc. (NASDAQ: THRX) is halted today. Headlines have an FDA panel voted 8 - 5 that breo ellipta helps reduce lung disease severity.
The panel also voted 12-1 that breo aids in airflow obstruction and reduces disease exacerbations.
Glaxo (NYSE: GSK) is a partner in development of the drug, which is being proposed as a treatment for COPD.
The panel also voted 12-1 that breo aids in airflow obstruction and reduces disease exacerbations.
Glaxo (NYSE: GSK) is a partner in development of the drug, which is being proposed as a treatment for COPD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hunterbrook bullish on Modine Manufacturing (MOD)
- UGI Corp. (UGI) halted on volatility, up 6%
- PSQ Holdings (PSQH) Halted, News Pending
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
